Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.
If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.
* Price is subject to applicable taxes.
Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.
(NewsDirect)
Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has embarked on a major strategic shift, focusing its commercial efforts on the BioOxi platform. To assist in this transition, Willow Biosciences has engaged an advisor to explore and evaluate potential opportunities.
This move is part of a broader strategy that also encompasses a collaborative venture with a Nasdaq-listed biopharmaceutical company. Together, they are working to establish sustainable manufacturing routes for key intermediates and active pharmaceutical ingredients.
Savile highlighted the company's achievements in executing successful commercial programs. Notably, four new programs linked to the BioOxi bio-oxidation platform technology were launched in April 2023.
Willow Biosciences is now concentrating on partner-funded enzyme engineering engagements, a strategic shift aimed at enhancing cost efficiency and optimizing the pathway to revenue growth.
This refocusing strategy aligns with the company's commitment to unlocking nearer-term and potentially larger revenue opportunities, particularly compared to its legacy strain engineering business.
Furthermore, Savile shared insights into the company's operational evolution. Willow Biosciences has completed a seamless transition, consolidating its operations into a single, cost-efficient facility located in Sunnyvale, California. This facility not only caters to the present needs of the company but also accommodates future growth prospects.
With ample laboratory space, Willow Biosciences can continue to expand its collaborative efforts while maintaining a financially prudent approach, in contrast to previous locations. bolstered by cost-effective operations and a focused commercial approach.
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.